TP53 and sarcoma: Sarcomas are a highly heterogeneous group of diseases comprising over 100 histological subtypes.1 p53 mutations, which affect approximately ~50% of sarcomas,2, 3 so far remain undruggable.4 No other common alterations have been identified across histologic subtypes.5 Metabolic abnormalities and dependencies are becoming recognized as opportunities for treatment,6 but none have yet to be identified in sarcomas as a high-frequency target.